Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Sells $18,223.74 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 2,466 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $7.39, for a total transaction of $18,223.74. Following the completion of the sale, the general counsel now directly owns 100,937 shares of the company’s stock, valued at $745,924.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Health Catalyst Price Performance

NASDAQ HCAT opened at $8.02 on Friday. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The company’s 50-day simple moving average is $7.00 and its 200 day simple moving average is $6.90.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. The company had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The business’s revenue was up 3.7% on a year-over-year basis. During the same period last year, the business earned ($0.21) earnings per share. On average, equities research analysts forecast that Health Catalyst, Inc. will post -0.35 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on HCAT shares. Evercore ISI cut their target price on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Tuesday, July 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a report on Tuesday, August 20th. JPMorgan Chase & Co. boosted their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Piper Sandler cut their price target on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. Finally, Stephens lowered their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.42.

Hedge Funds Weigh In On Health Catalyst

Institutional investors and hedge funds have recently bought and sold shares of the business. Los Angeles Capital Management LLC acquired a new stake in shares of Health Catalyst in the fourth quarter valued at $108,000. Charles Schwab Investment Management Inc. increased its position in Health Catalyst by 19.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 521,362 shares of the company’s stock valued at $4,828,000 after acquiring an additional 85,777 shares in the last quarter. Versor Investments LP raised its stake in shares of Health Catalyst by 150.0% in the fourth quarter. Versor Investments LP now owns 29,000 shares of the company’s stock worth $269,000 after acquiring an additional 17,400 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Health Catalyst by 437.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 253,368 shares of the company’s stock worth $2,346,000 after purchasing an additional 206,184 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Health Catalyst during the fourth quarter valued at approximately $645,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.